The Global Pain Therapeutics Market Market Analysis, R&D Pipelines and Competitive Landscape

Published by: Arrowhead Publishers

Published: Oct. 29, 2007 - 408 Pages

Table of Contents

1 METHODOLOGY AND EXECUTIVE SUMMARY

1.1 Research Methodology

1.2 Report Objectives and Scope

1.3 Executive Summary

2 CAUSES, CLASSIFICATIONS AND GLOBAL IMPACT OF PAIN

2.1 Causes

2.1.1 Terminal Illness

2.1.2 Pain and Genetics

2.1.3 The Immune System and Pain

2.1.4 The Subjective Nature of Pain

2.1.5 Pain Transmission

2.1.5.1 Nociceptors

2.1.5.2 Pain Receptors

2.2 Classifications of Pain

2.2.1 Chronic Pain

2.2.2 Acute Pain

2.3 The Impact of Pain

2.3.1 Demographic Impact of Pain

2.3.2 Financial Cost of Pain

3 TREATING PAIN: DRUG CLASSES AND GUIDELINES

3.1 NSAIDs

3.2 Opioids

3.2.1 Chronic Pain and Opioids

3.3 Antidepressants

3.4 Anticonvulsants

4 POST-OPERATIVE PAIN OVERVIEW AND THERAPEUTIC OPTIONS

4.1 Impact of Post-operative Pain

4.2 Pain Intensity in Surgical Sites

4.3 Site-Specific Pain Relief

4.4 Post-operative Medications

4.4.1 Naropin

4.4.2 DepoDur, DepoMorphine and Propofol

4.4.3 Other Opioids for Pain Management

4.4.4 NSAIDs for Post-operative Pain

5 BACK PAIN OVERVIEW AND THERAPEUTIC OPTIONS

5.1 Sciatica

5.2 Facet Joint Problems

5.3 Osteoarthritis

5.4 Diseases and Back Pain

5.5 Low Back Pain

5.6 Pharmaceutical Relief for Back Pain

5.6.1 Transdermal Patches

5.6.2 Injections for Back Pain

5.6.3 Back Pain and Opioids

5.6.4 Tricyclic Antidepressants

5.6.5 Muscle Relaxers

5.6.6 Colchicine

5.6.7 Chronic Low Back Pain and Anticonvulsants

6 NEUROPATHIC PAIN OVERVIEW AND THERAPEUTIC OPTIONS

6.1 Nociceptive Versus Neuropathic Pain

6.2 Nociceptive and Neuropathic Mixed Pain

6.3 Neuropathic Pain Generation

6.4 Treating Neuropathic Pain

6.4.1 Tricyclic Antidepressants

6.4.2 Duloxetine

6.4.3 Transdermal Fentanyl

6.4.4 Tramadol

6.4.5 Ketamine and Alfentanil

6.4.6 Neurontin

6.4.7 Lyrica

6.4.8 Carbamazepine

6.4.9 Lidocaine

7 MIGRAINE OVERVIEW AND THERAPEUTIC OPTIONS

7.1 Impact of Migraines

7.2 Pharmacological Treatment of Migraine Pain

7.2.1 Fiorinal and Fioricet

7.2.2 Ergot Alkaloid Derivatives

7.2.3 Triptans

7.2.3.1 Comparing Triptans

7.2.3.2 Imitrex

7.2.3.3 Zomig

7.2.3.4 Maxalt

7.2.3.5 Relpax

7.2.4 Neuroleptics

7.2.5 Beta-Blockers

7.3 Alternative Therapies for Migraine

8 CANCER PAIN OVERVIEW AND THERAPEUTIC OPTIONS

8.1 Causes of Cancer Pain

8.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Cancer Pain

8.3 Opioids and Cancer Pain

8.3.1 Reluctance to Prescribe Opioids

8.4 Seizure Drugs for Cancer Pain

9 ARTHRITIC PAIN OVERVIEW AND THERAPEUTIC OPTIONS

9.1 Impact of Arthritis

9.2 Rheumatoid Arthritis

9.2.1 Causes

9.2.2 RA Demographics

9.2.3 Genetic Susceptibility

9.2.4 Environmental Factors

9.2.5 High Cost of Rheumatoid Arthritis

9.3 Osteoarthritis

9.3.1 Causes

9.3.2 Pharmacological Treatment of Osteoarthritis

9.3.2.1 Cox-2 Class

9.3.3 Pharmacological Treatment of Rheumatoid Arthritis

9.4 Antirheumatic Drug Classes

9.4.1 Nonsteroidal Anti-Inflammatory Drugs

9.4.2 Corticosteroids

10 FIBROMYALGIA OVERVIEW AND THERAPEUTIC OPTIONS

10.1 Manifestations

10.2 Impact of Fibromyalgia

10.3 Natural Treatments for Fibromyalgia

10.4 Prescription Treatments for Fibromyalgia

10.4.1 Treatment with Antidepressants

10.4.2 Muscle Relaxants

10.4.3 Sleep Modifiers

10.4.4 Anxiety Medications

10.4.5 Anticonvulsants

10.4.6 Antibiotics

11 NON-PHARMACEUTICAL PAIN TREATMENT

11.1 Acupuncture

11.1.1 Assessing Acupuncture’s Value

11.2 Osteopathic Manipulation

11.2.1 Osteopathic Treatment

11.2.2 Conditions Treated by Osteopaths

11.3 Physiotherapy

11.4 Reflexology

11.5 Neurostructural Integration Technique

11.6 Herbal Medicine

11.7 Neurolytic Block Injections

11.7.1 Examples of Neurolytic Blocks

11.8 Chemical Neurolytic Blocks

11.9 Cryoablation

11.10 Radiofrequency Lesioning

11.11 Neurosurgical Procedures

11.12 Chemical Ablation

11.13 Nerve Blocks

11.14 Neurostimulation and Pain Control

11.15 Electro Thermal Disc Decompression/ Intradiscal Electro Thermocoagulation

11.16 Selective Nerve Root Injections

11.17 Facet Joint Pain Block

11.18 Trigger Spot Injections

11.19 Peripheral Nerve Injections

11.20 Cervical and Lumbar Epidural Blocks

11.21 Cognitive Behavioral Treatment (CBT)

12 NSAID USE AND MARKET ANALYSIS

12.1 Overview

12.2 Over-the-Counter NSAIDs

12.2.1 Ibuprofen

12.2.2 Naproxen

12.2.3 Acetaminophen and Aspirin

12.3 Traditional Prescription NSAIDs

12.3.1 Diclofenac/Cataflam/Voltaren

12.3.2 Arthrotec

12.3.3 Mobic

12.3.3.1 Mobic’s Market Performance

12.3.3.2 Mobic Vs Other NSAIDs

12.3.4 DayPro

12.3.4.1 Rheumatoid Arthritis Relief from DayPro

12.3.4.2 Osteoarthritis Relief from DayPro

12.3.5 Relafen

12.3.5.1 Relafen Versus Naproxen and Aspirin

12.3.5.2 Endoscopy Trials

12.4 The Future of the NSAID Market

12.5 Drivers and Constraints of the NSAID Market

13 OPIOID USE AND MARKET TRENDS

13.1 Drawbacks of Opioid Therapy

13.2 Treating Chronic Pain

13.3 Key Opioid Products

13.3.1 Morphine

13.3.1.1 Increased Usage of Morphine

13.3.1.2 Cognitive and Psychomotor Effects

13.3.1.3 Extended Release Morphine

13.3.1.3.1 Kadian

13.3.1.3.1.1 Kadian and Naltrexone

13.3.1.3.1.2 Key Clinical Trial

13.3.2 Codeine

13.3.3 Oxycodone

13.3.4 Vicodin

13.3.5 Ultracet/Ultram

13.3.6 Duragesic

13.3.7 Fentora

13.3.8 Ionsys

13.4 Legal Regulation of Opioids

13.5 Side Effects

13.6 Adjuvant Medications

13.7 Opioid Market Analysis

13.7.1 OxyContin

13.7.1.1 Abuse-Resistant OxyContin

13.7.1.2 Generic Competition

13.7.2 Duragesic

13.7.3 Kadian

13.7.4 Ultracet/Ultram

13.7.5 Avinza

13.7.6 Actiq

13.8 The Future of the Opioid Market

13.9 Drivers and Constraints of the Opioid Market

14 TRIPTANS THERAPY MARKET

14.1 Overview

14.2 Leading Migraine Therapies

14.2.1 Imitrex/Imigran

14.2.2 Zomig

14.2.3 Relpax

14.2.4 Maxalt

14.2.5 Frova

14.3 Preventive vs. Abortive Therapy

14.4 The Future of the Migraine Market

14.5 Drivers and Constraints of the Triptan Therapy Market

15 ANTICONVULSANT MARKET

15.1 Overview

15.2 Leading Anticonvulsants

15.2.1 Lyrica

15.2.2 Neurontin

15.2.3 Topamax

15.2.4 Depakote

15.2.5 Lamictal

15.2.6 Trileptal

15.2.7 Tegretol

15.3 The Future of the Anticonvulsant Market

15.4 Drivers and Constraints of the Anticonvulsant Market

16 COX-2 INHIBITORS AND THE FUTURE

16.1 The Fall of Bextra

16.1.1 Post-Marketing Reports for Bextra

16.1.2 Withdrawal of Bextra

16.2 The Fall of Vioxx

16.2.1 Repercussions from the Vioxx Withdrawal

16.3 Celebrex: Surviving the Fallout

16.3.1 Black Box Warning

16.4 Cox-2 Pipeline

16.4.1 Prexige

16.4.1.1 TARGET Assessment

16.4.1.2 Future of Prexige

16.4.2 Arcoxia

16.4.3 Dynastat

16.5 The Future of the Cox-2 Class

16.6 Drivers and Constraints of the Cox-2 Market

17 PRODUCTS IN DEVELOPMENT

17.1 Key Opioid Products in Development

17.1.1 Sufentanil Patches

17.1.2 Chronogesic

17.1.3 Remoxy

17.1.4 Rapinyl

17.1.5 Hydromorphone Patches

17.1.6 M6G

17.2 Key Migraine Pain Therapies in Development

17.2.1 AZ-001

17.2.2 PRO-513

17.2.3 MK-0974

17.2.4 Botox

17.2.5 Trexima

17.2.6 Dysport

17.2.7 NovaDel

17.2.8 Zogenix

17.3 Key Cancer Pain Therapies in Development

17.3.1 Rapinyl

17.3.2 Remoxy

17.3.3 Sativex

17.3.4 Ziconatide

17.3.5 Chronogesic Pain Therapy System

17.3.6 ASICs

17.3.7 Xen2174

17.4 Key Fibromyalgia Therapies in Development

17.4.1 Cymbalta

17.4.2 Pristiq (desvenlafaxine)

17.4.3 Milnacipran

17.4.4 Xyrem (sodium oxybate)

17.4.5 Other Fibromyalgia Research Areas

17.5 Key Post-operative Pain Therapies in Development

17.5.1 LidoPAIN SP

17.5.2 Dyloject

17.5.3 M6G

17.5.4 ROX-888

17.6 Key Neuropathic Pain Therapies in Development

17.6.1 Fentora

17.6.2 NGX-4010

17.6.3 NP-1

17.6.4 Cannabinor (CB2) IV

17.6.5 V3381

17.7 Emerging Novel Drug Classes

17.8 Comparative Analysis of Emerging Therapies

18 THE ROLE OF DRUG DELIVERY IN EMERGING PAIN THERAPEUTICS

18.1 Delivery Options for Pain Therapeutics

18.2 Emerging Technologies for Delivery of Pain Therapeutics

18.2.1 Delivery Devices

18.2.2 More Convenient Administration Routes

19 PROMISING AREAS OF RESEARCH

19.1 Natural Painkillers

19.2 Peptides

19.3 Epibatidine

19.4 Willow Bark

19.5 Chilli Peppers and Capsaicin

19.6 Cannabinoids

19.7 Receptors as Gateways

19.8 Chromaffin Cells

19.9 Homeopathic Remedies

19.10 Ion Channels

19.10.1 Calcium Channel Blockers

19.10.1.1 Case Study: Prialt

19.10.2 Sodium Channel Blockers

19.10.2.1 Tetrodotoxin

19.10.3 Vanilloid Receptors

19.10.4 Glutamate Receptor Antagonists

19.10.4.1 NMDA-Receptor Antagonists

19.11 NSRI Agents

20 COMPANY BRIEFS

20.1 Abbott Laboratories

20.2 Alexza Pharmaceuticals

20.3 Alpharma

20.4 Altea Therapeutics

20.5 Amgen

20.6 Anesiva

20.7 Aradigm

20.8 Argolyn Bioscience

20.9 AstraZeneca

20.10 Avigen

20.11 Bayer Schering

20.12 Baxter

20.13 Biogen Idec

20.14 Biovail

20.15 Boehringer Ingelheim

20.16 Bristol-Myers Squibb

20.17 Cadence Pharmaceuticals

20.18 CeNeS Pharmaceuticals

20.19 Cephalon

20.20 Cerimon Pharmaceuticals

20.21 Cipher Pharmaceuticals

20.22 CombinatoRx

20.23 Cypress Bioscience

20.24 Depomed

20.25 Durect Corporation

20.26 Eisai

20.27 Elan Pharmaceuticals

20.28 Eli Lilly

20.29 Elite Pharmaceuticals

20.30 Endo Pharmacuticals

20.31 Enhance Biotech (formerly Ardent Pharma)

20.32 EpiCept

20.33 Evotec Neurosciences

20.34 FemmePharma Global Healthcare

20.35 Forest Laboratories

20.36 GlaxoSmithKline

20.37 GW Pharmaceuticals

20.38 Horizon Therapeutics

20.39 Icagen

20.40 Indevus Pharmaceuticals

20.41 Innocoll Pharma

20.42 Ista Pharmaceuticals

20.43 Javelin Pharmaceuticals

20.44 Johnson & Johnson

20.45 Kalypsys

20.46 King Pharmaceuticals

20.47 Labopharm

20.48 Medtronic

20.49 Merck & Co

20.50 MGI Pharma

20.51 Nastech Pharmaceutical

20.52 NeuroCure

20.53 Neurocrine Biosciences

20.54 NeurogesX

20.55 Neuromed Pharmaceuticals

20.56 Neurorecovery

20.57 NovaDel

20.58 Novartis Pharmaceuticals

20.59 Noven

20.60 Nuvo Research

20.61 Organon

20.62 PainCeptor Pharma

20.63 Pain Therapeutics

20.64 Penwest

20.65 Pfizer

20.66 Pharmos

20.67 Phosphagenics

20.68 Pozen

20.69 ProEthic Pharmaceuticals

20.70 Purdue

20.71 Questcor Pharmaceuticals

20.72 Quigley Pharma

20.73 Renovis

20.74 Roche

20.75 RoxRo Pharma

20.76 Sanofi-Aventis

20.77 Sepracor

20.78 SkyePharma

20.79 Sosei

20.80 Symbollon

20.81 Tanabe Seiyaku

20.82 Targacept

20.83 TheraQuest Biosciences

20.84 TorreyPines Therapeutics

20.85 UCB Pharma

20.86 Vernalis

20.87 Vertex Pharmaceuticals

20.88 Victory Pharma

20.89 Wex Pharmaceuticals

20.90 Wyeth

20.91 Xenome

20.92 XenoPort

20.93 XTL Biopharmaceuticals

20.94 YM Biosciences

20.95 ZARS Pharma

20.96 Zogenix

APPENDICES

APPENDIX I

APPENDIX II

APPENDIX III

TABLES

Table 1.1 Value of the Pain Market by Therapeutic Class 2004 and 2006 ($ mn)

Table 1.2 Top 20 Pain Medications Worldwide in 2006 ($ mn)

Table 2.1 Characteristics and Treatment of Acute vs Chronic Pain

Table 2.2 Incidence of Pain Conditions in American Households

Table 3.1 Key Pain Management Drug Classes and Diseases/Conditions Treated

Table 3.2 NSAID Delivery Routes

Table 3.3 Traditional NSAIDs

Table 3.4 The Oxford League Table of Analgesic Efficacy

Table 3.5 Opioid Delivery Routes

Table 3.6 Well-Known Narcotic Analgesics

Table 3.7 Antidepressant Delivery Routes

Table 3.8 WHO Guidelines for Pain Therapy

Table 4.1 WFSA Analgesic Ladder

Table 6.1 Common Etiologies of Neuropathic Pain

Table 6.2 Drug Interactions of the Agents Used to Treat Neuropathic Pain

Table 7.2 Popular Medicines for the Treatment of Migraine

Table 7.3 Preventive Headache Therapies

Table 7.4 Common Analgesics Prescribed for Mild Migraine Pain

Table 7.5 Ergot Alkaloid Derivatives for Migraine Pain

Table 7.6 NSAIDs and Cox-2 Inhibitors for Migraine Pain

Table 7.7 Triptans for Migraine Pain

Table 7.8 Patent Expirations for Leading Triptans

Table 8.1 Cancer Pain and Therapeutic Options

Table 8.2 Adjuvants to Opioids for Treating Cancer Pain

Table 8.3 Other Treatments for Cancer Pain

Table 8.4 Anticonvulsants for Cancer Pain

Table 9.1 Leading Causes of Years of Life Lost Due to a Disability for Both Sexes of All Ages

Table 9.2 Financial Impact of Employees Suffering RA

Table 10.1 Popular Treatments for Fibromyalgia

Table 11.1 Complementary and Alternative Medicine Use by US Adults (2002)

Table 11.2 Ten Most Common Complementary and Alternative Therapies (2002)

Table 11.3 Disease/Condition Most Frequently Treated with Complementary/Alternative Medicines

Table 12.1 Global Sales of Leading Prescription NSAIDs (Traditional) 2006

Table 12.2 Cox-2 NSAIDs

Table 12.3 Prescription and OTC Non-Selective NSAIDs

Table12.4 Sales of Advil* 2002-2006 ($mn)

Table 12.5 Financial Forecast of Ibuprofen Sales 2007-2011 ($ mn)

Table 12.6 Sales of Aleve 2002-2006 (€ mn)

Table 12.7 Sales of Aspirin 2005-2006 (€ mn)

Table 12.8 Sales of Excedrin* 2002-2004 ($ mn)

Table 12.9 Sales of Voltaren 2003-2006 ($ mn)

Table 12.10 Financial Forecast of Voltaren Sales 2007-2011 ($ mn)

Table 12.11 Sales of Mobic 2003-2006 (€ mn)

Table 12.12 Financial Forecast of Mobic Sales 2007-2011 ($ mn)

Table 12.13 Adverse Events (%) Occurring in ≥2% of Mobic Patients in a 12-Week Osteoarthritis Placebo and Active-Controlled Trial

Table 12.14 Financial Forecast of the NSAID Market 2007-2011 ($ mn)

Table 13.1 Overview of Opioid Analgesics

Table 13.2 Key Opioid Product Sales 2006

Table 13.3 Global Sales of OxyContin 2003-2006 ($ mn)

Table 13.4 Financial Forecast of OxyContin Sales 2007-2011 ($ mn)

Table 13.5 Percent of US Household Population 12 Years and Older Reporting Past Month Non-Medical Use of Physchotherapeutics

Table 13.6 Global Sales of Duragesic 2001-2006 ($ mn)

Table 13.7 Financial Forecast of Duragesic Sales 2007-2011 ($ mn)

Table 13.8 Global Sales of Kadian 2002-2006 ($ mn)

Table 13.9 Global Sales of Ultracet/Ultram 2001-2006 ($ mn)

Table 13.10 Global Sales of Avinza 2003-2006 ($ mn)

Table 13.11 Global Sales of Actiq 2002-2006 ($ mn)

Table 13.12 Financial Forecast of Actiq Sales 2007-2011 ($ mn)

Table 13.13 Financial Forecast of the Global Opioid Market 2006-2006 ($ mn)

Table 14.1 Sales of Triptan Drugs 2001-2006

Table 14.2 Sales of Leading Migraine Therapies 2006

Table 14.3 Sales of Imitrex/Imigran 2001-2006 ($ mn)

Table 14.4 Financial Forecast of Imitrex/Imigran Sales 2007-2011 ($ mn)

Table 14.5 Sales of Zomig 2001-2006 ($ mn)

Table 14.6 Financial Forecast of Zomig Sales 2007-2011 ($ mn)

Table 14.7 Sales of Relpax 2001-2006 ($ mn)

Table 14.8 Sales of Maxalt 2001-2006 ($ mn)

Table 14.9 Sales of Frova 2005-2006 ($ mn)

Table 14.10 Financial Forecast of Triptans 2007-2011 ($ mn)

Table 15.1 Leading Anticonvulsants, Global Sales 2006

Table 15.2 Sales Growth in the Anticonvulsants Market 2001-2006 ($ mn)

Table 15.3 Leading Anticonvulsants Indications

Table 15.4 Sales of Lyrica 2001-2006 ($ mn)

Table 15.5 Financial Forecast of Lyrica Sales 2007-2011 ($ mn)

Table 15.6 Sales of Neurontin 2001-2006 ($ mn)

Table 15.7 Sales of Topamax 2001-2006 ($ mn)

Table 15.8 Financial Forecast of Topamax Sales 2007-2011 ($ mn)

Table 15.9 Sales of Depakote 2001-2006 ($ mn)

Table 15.10 Financial Forecast of Depakote Sales 2007-2011 ($ mn)

Table 15.11 Sales of Lamictal 2001-2006 ($ mn)

Table 15.12 Financial Forecast of Lamictal Sales 2007-2011 ($ mn)

Table 15.13 Sales of Trileptal 2001-2006 ($ mn)

Table 15.14 Sales of Tegretol 2001-2006 ($ mn)

Table 15.15 Financial Forecast of the Anticonvulsant Market 200-2011 ($ mn)

Table 16.1 Leading Cox-2 Inhibitors 2004 ($ mn)

Table 16.2 Sales of Celebrex 2003-2006 ($ mn)

Table 16.3 Sales of Arcoxia 2003-2006 ($ mn)

Table 16.4 Post-Bextra Switching Trends

Table 16.5 Future Sales of Celebrex

Table 17.1 Migraine Drugs in Development

Table 17.2 Other Fibromyalgia Treatments in Development

Table 17.3 Promising Areas of Fibromyalgia Research

Table 17.4 Key Pipeline Products and Their Potential in Pain Management

Table 18.1 Most Common Delivery Routes for Pain Therapeutics

Table 20.1 Alexza’s Pain Therapeutics Pipeline

Table 20.2 Amgen’s Pain Therapeutics Pipeline

Table 20.3 Avigen’s Pain Therapeutics Pipeline

Table 20.4 Cadence’s Pain Therapeutics Pipeline

Table 20.5 CeNeS Pharmaceuticals’ Pain Therapeutics Pipeline

Table 20.6 Depomed’s Therapeutics Pipeline

Table 20.7 Durect’s Pain Therapeutics Pipeline

Table 20.8 Eisai’s Pain Therapeutics Pipeline

Table 20.9 Elite’s Pain Therapeutics Pipeline

Table 20.10 Evotec’s Pain Therapeutics Pipeline

Table 20.11 Horizon’s Pain Therapeutics Pipeline

Table 20.12 Javelin Pharmaceuticals’ Pain Therapeutics Pipeline

Table 20.13 Kalypsys’ Pain Therapeutics Pipeline

Table 20.14 Pfizer’s Pain Therapeutics Pipeline

Table 20.15 Pozen’s Pain Therapeutics Pipeline

Table 20.16 Purdue’s Pain Therapeutics Portfolio

Table 20.17 Victory’s Pain Therapeutics Pipeline

Table 20.18 XenoPort’s Pain Therapeutics Pipeline

Table I Global Sales of Leading Pain Management Drugs 2006

Table II Key Pipeline Pain Therapeutics

Table III Acute Pain Pipeline

Table IV Chronic Pain Pipeline

Table V Neuropathic Pain Pipeline

Table VI Post-operative Pain Pipeline

Table VII Migraine Pain Pipeline

Table VIII Rheumatoid Arthritis Pain Pipeline

Table IX Cancer Pain Pipeline

Table X NSAIDs Affected by Newly Required Warning Labels

GRAPHS

Graph 1.1 Pain Therapeutics Market Share by Class 2006

Graph 2.1 Top Causes of Pain

Graph 7.1 Difference in Prevalence of Migraine Headache among Men and Women by Age

Graph 9.1 Percentage of Adults with Diabetes, Heart Disease, or High Blood Pressure Who Also Have Arthritis

Graph 12.1 Prescription NSAID Product Market Share (Traditional vs Cox-2 Inhibitors) 2006

Graph 12.2 Prescription NSAID Product Market Share 2006

Graph 12.3 Sales of Advil 2002-2006

Graph 12.4 Sales of Aleve 2002-2006

Graph 12.5 Sales of Aspirin 2005-2006

Graph 12.6 Global Sale of Excedrin 2002-2004

Graph 12.7 Sales of Voltaren 2003-2006

Graph 12.8 Sales of Mobic 2003-2006

Graph 13.1 Global Market Share of Branded Opioid Products 2006

Graph 13.3 Global Sales of OxyContin 2003-2006

Graph 13.4 Global Sales of Duragesic 2001-2006

Graph 13.5 Global Sales of Kadian 2002-2006

Graph 13.3 Global Sales of Ultracet/Ultram 2001-2006

Graph 13.7 Global Sales of Avinza 2003-2006

Graph 13.8 Global Sales of Actiq 2002-2006

Graph 13.9 Financial Forecast of the Global Opioid Market 2006-2006

Graph 14.1 Sales of Triptan Drugs 2001-2006

Graph 14.2 Leading Migraine Therapies, Market Share 2006

Graph 14.3 Geographic Market Share of Leading Triptan-Based Migraine Therapies 2006

Graph 14.4 Sales of Imitrex/Imigran 2001-2006

Graph 14.5 Sales of Zomig 2001-2006

Graph 14.6 Sales of Relpax 2001-2006

Graph 14.7 Sales of Maxalt 2001-2006

Graph 14.8 Sales of Frova 2005-2006

Graph 15.1 Leading Anticonvulsants, Market Share 2006

Graph 15.2 Sales Growth in the Anticonvulsants Market 2001-2006 ($ mn)

Graph 15.3 Sales of Lyrica 2004-2006

Graph 15.4 Sales of Neurontin 2001-2006

Graph 15.5 Sales of Topamax 2001-2006

Graph 15.6 Sales of Depakote 2001-2006

Graph 15.7 Sales of Lamictal 2001-2006

Graph 15.8 Sales of Trileptal 2001-2006

Graph 15.9 Sales of Tegretol 2001-2006

Graph 16.2 Sales of Arcoxia 2003-2006

Graph 16.1 Sales of Celebrex 2003-2006

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.